Evaluation of menogaril in renal cell carcinoma
dc.contributor.author | Stephens, Ronald L. | en_US |
dc.contributor.author | Goodman, Phyllis | en_US |
dc.contributor.author | Crawford, E. David | en_US |
dc.contributor.author | Spicer, Connie F. | en_US |
dc.contributor.author | Lowe, Bruce A. | en_US |
dc.contributor.author | Ahmann, Frederick R. | en_US |
dc.contributor.author | Chapman, Robert | en_US |
dc.contributor.author | Natale, Ronald B. | en_US |
dc.date.accessioned | 2006-09-11T15:57:06Z | |
dc.date.available | 2006-09-11T15:57:06Z | |
dc.date.issued | 1990-03 | en_US |
dc.identifier.citation | Stephens, Ronald L.; Goodman, Phyllis; Crawford, E. David; Spicer, Connie F.; Lowe, Bruce A.; Ahmann, Frederick R.; Chapman, Robert; Natale, Ronald B.; (1990). "Evaluation of menogaril in renal cell carcinoma." Investigational New Drugs 8(1): S69-S71. <http://hdl.handle.net/2027.42/45344> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45344 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2143177&dopt=citation | en_US |
dc.description.abstract | The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m 2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer. | en_US |
dc.format.extent | 251137 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Menogaril | en_US |
dc.subject.other | Renal Cell Carcinoma | en_US |
dc.title | Evaluation of menogaril in renal cell carcinoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, USA | en_US |
dc.contributor.affiliationother | University of Kansas Medical Center, USA | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, USA | en_US |
dc.contributor.affiliationother | University of Colorado, USA | en_US |
dc.contributor.affiliationother | University of Kansas Medical Center, USA | en_US |
dc.contributor.affiliationother | Oregon Health Sciences University, Arizona, USA | en_US |
dc.contributor.affiliationother | University of Arizona, USA | en_US |
dc.contributor.affiliationother | Henry Ford Hospital, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2143177 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45344/1/10637_2004_Article_BF00171987.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00171987 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.